TVA Medical: TVA Medical gets FDA de novo marketing clearance for everlinQ endoAVF system
TVA Medical has secured de novo marketing authorization from the US Food and Drug Administration (FDA) for its everlinQ endoAVF system.
Read full article »
CEO
TVA Medical develops and manufactures a catheter-based system for the creation of an arteriovenous fistula in patients requiring hemodialysis.
Read more